Zobrazeno 1 - 10
of 23
pro vyhledávání: '"J H, McVey"'
Publikováno v:
European Heart Journal. 42
Introduction Routine cardiovascular interventions such as cardiac bypass, balloon angioplasty and stenting provoke vascular activation and remodelling often leading to rehospitalization and further interventions. Conventional in vitro models fail to
Autor:
Jonathan D. Johnston, Rolando S Matos, Eirini Velliou, Paolo Madeddu, Valeria Mastrullo, J H McVey, P Gupta, D. R. van der Veen, Paola Campagnolo
Publikováno v:
European Heart Journal. 42
Background/Introduction Circadian rhythms, defined as biological oscillations with a period of circa 24h, regulate many physiological processes in the cardiovascular system, such as vascular function, vascular tone, blood pressure, heart rate and thr
Autor:
K M, Johnson, J H, McVey
Publikováno v:
Methods in molecular medicine. 31
Factor XI (FXI) is the zymogen precursor of an active serine protease that participates in the contact phase of coagulation. Synthesized in the liver, it circulates in the plasma in a noncovalent complex with high molecular weight kininogen (1) at a
Publikováno v:
Blood. 75:688-695
We examined the effect of cytokines on basal and agonist-stimulated release of von Willebrand factor (vWf) by human endothelial cells. Treatment of endothelial cells for up to 48 hours with human recombinant or purified interleukin 1 (IL-1) or human
Autor:
A D, Mumford, J H, McVey, C V, Morse, K, Gomez, M, Steen, E A, Norstrom, E G D, Tuddenham, B, Dahlback, P H B, Bolton-Maggs
Publikováno v:
British journal of haematology. 123(3)
We report a kindred in which two siblings suffered spontaneous venous thromboses in the second decade of life. Further investigation showed reduced coagulation factor V (FV) activity and activated protein C resistance (APCR) ratio but no other thromb
Publikováno v:
Xenotransplantation. 8(4)
Aside from their critical role in thrombosis, activated coagulation factors also have inflammatory properties and these may be important during delayed xenograft rejection (DXR). This study assessed whether porcine EC could be activated by factor Xa
Autor:
D, David, E L, Saenko, I M, Santos, D J, Johnson, E G, Tuddenham, J H, McVey, G, Kemball-Cook
Publikováno v:
British journal of haematology. 113(3)
In haemophilia A, the functional defect at the molecular level of most factor VIII (FVIII) missense mutations remains unknown. Site-directed mutagenesis of B domain-deleted FVIII cDNA (FVIIISQ) was used to introduce two mutations associated with seve
Publikováno v:
Human mutation. 17(1)
Factor VII (FVII) is a zymogen for a vitamin K-dependent serine protease essential for the initiation of blood coagulation. It is synthesized primarily in the liver and circulates in plasma at a concentration of approximately 0.5 microg/ml (10 nmol/L
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 4(4)
Inhibitor development is now the main complication of replacement therapy in haemophilia A. Given that most severely affected patients make no detectable factor VIII, it is perhaps surprising that only approximately 30% actually mount an immune respo
Publikováno v:
Thrombosis and haemostasis. 80(4)
High FVIII:C levels have previously been shown to be an independent risk factor for thrombosis with 4.8 times higher potential risk of thrombosis in individuals with FVIII:C levels greater than 1.5 u/ml. Recently, we found that raised FVIII:C levels